Company Description

Esphera SynBio designs transgenes encoding multimeric proteins that traffic into budding exosomes. Esphera’s lead application of this platform technology is the modification of tumour cells in vivo such that typically protumourigenic and immunosuppressive tumour-derived exosomes become immunostimulatory, antigen-bearing modifiers of the TME and bespoke, patient specific cancer vaccines.